Literature DB >> 18988803

Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Faris Farassati1, Weihong Pan, Farnaz Yamoutpour, Susann Henke, Mark Piedra, Silke Frahm, Said Al-Tawil, Wells I Mangrum, Luis F Parada, Samuel D Rabkin, Robert L Martuza, Andreas Kurtz.   

Abstract

Lack of expression of neurofibromin in neurofibromatosis 1 and its lethal derivative, malignant peripheral nerve sheath tumors (MPNSTs), is thought to result in the overactivation of the Ras signaling pathway. Our previous studies have shown that cells with overactivation in the Ras pathway are more permissive to infection with herpes simplex virus 1 and its mutant version R3616. In this study, we show that among five different mouse MPNST cell lines, only the ones with elevated levels of Ras signaling are highly permissive to infection with oncolytic herpes G207. Specific inhibitors of the Ras, ERK, and JNK pathways all reduced the synthesis of viral proteins in MPNST cells. The cell lines that contained lower levels of Ras and decreased activation of downstream signaling components underwent an enhancement in apoptosis upon exposure to G207. Additionally, mouse SW10 Schwann cells were able to become infected by parental herpes but were found to be resistant to G207. The immortalization of these cell lines with the expression of SV40 large T antigen increased the levels of Ras activation and permissiveness to oncolytic herpes. A Ras/Raf kinase inhibitor reduced the synthesis of both herpes simplex virus-1 and G207 proteins in SW10 cells. The results of this study, therefore, introduce Ras signaling as a divergent turning point for the response of MPNST cells to an assault by oncolytic herpes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18988803      PMCID: PMC2626396          DOI: 10.2353/ajpath.2008.080376

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  75 in total

Review 1.  Oncolytic viruses and cancer therapy.

Authors:  K L Norman; F Farassati; P W Lee
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

2.  Ras activation of phosphatidylinositol 3-kinase and Akt.

Authors:  P Rodriguez-Viciana; J Downward
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

3.  Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Authors:  C M Rudin; J Holmlund; G F Fleming; S Mani; W M Stadler; P Schumm; B P Monia; J F Johnston; R Geary; R Z Yu; T J Kwoh; F A Dorr; M J Ratain
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

4.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

Review 5.  Neurofibromatosis 1.

Authors:  Timothy M Lynch; David H Gutmann
Journal:  Neurol Clin       Date:  2002-08       Impact factor: 3.806

6.  Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.

Authors:  R Plattner; S Gupta; R Khosravi-Far; K Y Sato; M Perucho; C J Der; E J Stanbridge
Journal:  Oncogene       Date:  1999-03-11       Impact factor: 9.867

Review 7.  Ras signaling in prostate cancer progression.

Authors:  Michael J Weber; Daniel Gioeli
Journal:  J Cell Biochem       Date:  2004-01-01       Impact factor: 4.429

Review 8.  Cytogenetics and molecular genetics of nervous system tumors.

Authors:  J A Rey; A Pestaña; M J Bello
Journal:  Oncol Res       Date:  1992       Impact factor: 5.574

Review 9.  Mitogen-activated protein kinase signaling.

Authors:  Svetlana V Kyosseva
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

Review 10.  Ras/Raf/ERK signalling and NF1.

Authors:  Marie C Harrisingh; Alison C Lloyd
Journal:  Cell Cycle       Date:  2004-10-17       Impact factor: 4.534

View more
  17 in total

1.  Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.

Authors:  Haiping Zhou; Hong-ying Huang; Ellen Shapiro; Herbert Lepor; William C Huang; Moosa Mohammadi; Ian Mohr; Moon-shong Tang; Chuanshu Huang; Xue-ru Wu
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

Review 2.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

3.  The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.

Authors:  Janice M Kraniak; Daochun Sun; Raymond R Mattingly; John J Reiners; Michael A Tainsky
Journal:  Mol Cell Biochem       Date:  2010-08-01       Impact factor: 3.396

4.  Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Authors:  J D Jackson; A M McMorris; J C Roth; J M Coleman; R J Whitley; G Y Gillespie; S L Carroll; J M Markert; K A Cassady
Journal:  Gene Ther       Date:  2014-08-14       Impact factor: 5.250

5.  RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).

Authors:  Mohamad Ezzeldin; Emma Borrego-Diaz; Mohammad Taha; Tuba Esfandyari; Amanda L Wise; Warner Peng; Alex Rouyanian; Atabak Asvadi Kermani; Mina Soleimani; Elham Patrad; Kristina Lialyte; Kun Wang; Stephen Williamson; Bashar Abdulkarim; Mojtaba Olyaee; Faris Farassati
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

6.  Overactivation of Ras signaling pathway in CD133+ MPNST cells.

Authors:  Emma Borrego-Diaz; Kaoru Terai; Kristina Lialyte; Amanda L Wise; Tuba Esfandyari; Fariba Behbod; Victor F Mautner; Melanie Spyra; Sarah Taylor; Luis F Parada; Meena Upadhyaya; Faris Farassati
Journal:  J Neurooncol       Date:  2012-04-08       Impact factor: 4.130

7.  Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.

Authors:  Tuba Esfandyari; Ayalew Tefferi; Anna Szmidt; Tommy Alain; Pawel Zwolak; Terra Lasho; Patrick W Lee; Faris Farassati
Journal:  Mol Oncol       Date:  2009-07-28       Impact factor: 6.603

8.  Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Authors:  Slawomir Antoszczyk; Melanie Spyra; Victor Felix Mautner; Andreas Kurtz; Anat O Stemmer-Rachamimov; Robert L Martuza; Samuel D Rabkin
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

9.  STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.

Authors:  Joshua D Jackson; James M Markert; Li Li; Steven L Carroll; Kevin A Cassady
Journal:  Mol Cancer Res       Date:  2016-02-16       Impact factor: 5.852

10.  Reciprocal regulation of AKT and MAP kinase dictates virus-host cell fusion.

Authors:  Nishi R Sharma; Prashant Mani; Neha Nandwani; Rajakishore Mishra; Ajay Rana; Debi P Sarkar
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.